Burning Rock Biotech (BNR)
(Delayed Data from NSDQ)
$8.62 USD
+0.21 (2.50%)
Updated Sep 19, 2025 03:35 PM ET
After-Market: $8.51 -0.11 (-1.28%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNR 8.62 +0.21(2.50%)
Will BNR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BNR based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BNR
Is BNR positioned for a breakout? Crossed Above 20 Day Moving Average shows up after rising 2.5%
BNR forms NR7 on September 18
NR7 appears for BNR after 2.59% move
Is BNR likely to continue lower? 20 Day Moving Average Resistance shows up after sliding 2.53%
20 Day Moving Average Resistance appears for BNR after 4.94% move